Zynex Introduces New Product Line
Published: 2009-07-07 11:34:43
Author: Zynex | June 23, 2009
LITTLETON, Colo., Jun 23, 2009 (BUSINESS WIRE) -- ZYXI | Quote | Chart | News | PowerRating -- Zynex, Inc. (OTCBB: ZYXI), a provider of pain management systems and electrotherapy products for medical patients with functional disability, has introduced a Lumbar Sacral Orthosis (LSO) Back Support to its sales force effective immediately. The product is manufactured by a subsidiary of the British company BSN Medical and already has established reimbursement coding and pricing with insurance carriers as well as Medicare. The product is available in 8 different sizes, provides support for the lumbar area and is usually prescribed by physicians for Chronic Back Pain, Lumbar Instability, Herniated Lumbar Discs, Degenerative Disc Disease, Spondylosis, Stenosis and Post-Op Rehabilitation.
Zynex's CEO, Thomas Sandgaard, commented: "We are excited to add this product to our existing line of electrotherapy products. It lends itself well to the market for pain management and our existing sales force will have a more complete offering for doctors and patients."
About Zynex
Zynex, Inc. (founded in 1996) engineers, manufactures, markets and sells its own design of electrotherapy medical devices in two distinct markets: standard digital electrotherapy products for pain relief and pain management; and the NeuroMove(TM) for stroke and spinal cord injury (SCI) rehabilitation. Zynex's product lines are fully developed, FDA-cleared, commercially sold, and have been developed to uphold the Company's mission of improving the quality of life for patients suffering from impaired mobility due to stroke, spinal cord injury, or debilitating and chronic pain
Safe Harbor Statement
Certain statements in this release are "forward-looking" and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain additional capital in order to grow our business, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement from insurance companies for products sold or rented to our customers, acceptance of our products by health insurance providers, acceptance of our products by hospitals and clinicians, our dependence on third party manufacturers to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force, the uncertain outcome of pending material litigation and other risks described in our 10-K Report for the year ended December 31, 2008.
SOURCE: Zynex, Inc.
Zynex, Inc.
Thomas Sandgaard, CEO, 303-703-4906
www.zynexmed.com
Trading Markets
Published: 2009-07-07 11:34:43
Author: Zynex | June 23, 2009
LITTLETON, Colo., Jun 23, 2009 (BUSINESS WIRE) -- ZYXI | Quote | Chart | News | PowerRating -- Zynex, Inc. (OTCBB: ZYXI), a provider of pain management systems and electrotherapy products for medical patients with functional disability, has introduced a Lumbar Sacral Orthosis (LSO) Back Support to its sales force effective immediately. The product is manufactured by a subsidiary of the British company BSN Medical and already has established reimbursement coding and pricing with insurance carriers as well as Medicare. The product is available in 8 different sizes, provides support for the lumbar area and is usually prescribed by physicians for Chronic Back Pain, Lumbar Instability, Herniated Lumbar Discs, Degenerative Disc Disease, Spondylosis, Stenosis and Post-Op Rehabilitation.
Zynex's CEO, Thomas Sandgaard, commented: "We are excited to add this product to our existing line of electrotherapy products. It lends itself well to the market for pain management and our existing sales force will have a more complete offering for doctors and patients."
About Zynex
Zynex, Inc. (founded in 1996) engineers, manufactures, markets and sells its own design of electrotherapy medical devices in two distinct markets: standard digital electrotherapy products for pain relief and pain management; and the NeuroMove(TM) for stroke and spinal cord injury (SCI) rehabilitation. Zynex's product lines are fully developed, FDA-cleared, commercially sold, and have been developed to uphold the Company's mission of improving the quality of life for patients suffering from impaired mobility due to stroke, spinal cord injury, or debilitating and chronic pain
Safe Harbor Statement
Certain statements in this release are "forward-looking" and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain additional capital in order to grow our business, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement from insurance companies for products sold or rented to our customers, acceptance of our products by health insurance providers, acceptance of our products by hospitals and clinicians, our dependence on third party manufacturers to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force, the uncertain outcome of pending material litigation and other risks described in our 10-K Report for the year ended December 31, 2008.
SOURCE: Zynex, Inc.
Zynex, Inc.
Thomas Sandgaard, CEO, 303-703-4906
www.zynexmed.com
Trading Markets